Through our participation in the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMRTC) and the Children’s Oncology Group (COG), the largest pediatric cancer cooperative group in the world, we offer multiple clinical trials.
Below is a list of open clinical trials. Please check the website often for new and closed studies.
NMTRC005 – A Randomized, Phase I/II trial of Irinotecan and Temozolomide compared to Irinotecan and Temozolomide in Combination with TPI 287 in Patients with Primary Refractory or Early Relapsed Neuroblastoma.
NMTRC006 – An Intermediate Expanded Use Trial of DFMO (eflornithine HCl) as a Single Agent
(COG) ANBL1221– A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
ANBL00B1- Neuroblastoma Biology Studies: Companion to Therapeutic Protocols:
- (COG) http://clinicaltrials.gov/ct2/show/NCT00904241?term=ANBL00B1&rank=1
For a complete listing of open clinical trials that are available nationwide, visit clinicaltrials.gov.